AVGO
20
-5
UPS
41
-4
HOG
29
-4
A
36
2
TGT
25
-24
SYK
64
-4
VRTX
46
2
CF
59
3
EQT
59
2
JNJ
41
2
DOV
61
-2
TAP
58
-2
GM
65
-3
HSIC
54
-3
CINF
47
2
DNB
78
6
HSY
34
3
QCOM
48
-7
VRSK
73
5
CAG
30
4
AVGO
20
-5
UPS
41
-4
HOG
29
-4
A
36
2
TGT
25
-24
SYK
64
-4
VRTX
46
2
CF
59
3
EQT
59
2
JNJ
41
2
DOV
61
-2
TAP
58
-2
GM
65
-3
HSIC
54
-3
CINF
47
2
DNB
78
6
HSY
34
3
QCOM
48
-7
VRSK
73
5
CAG
30
4
Financhill
Back

Autolus Therapeutics PLC 10K Form

Sell
50

AUTL
Autolus Therapeutics PLC

Last Price:
2.79
Seasonality Move:
0.84%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AUTL News And Ratings

See the #1 stock for the next 7 days that we like better than AUTL

AUTL Financial Statistics

Sales & Book Value

Annual Sales: $1.7M
Cash Flow: $-86.33M
Price / Cash Flow: 0
Annual Sales: $1.79
Price / Book: 1.67

Profitability

EPS (TTM): -1.22000
Net Income (TTM): $-270.23M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Autolus Therapeutics PLC Earnings Forecast

Key Autolus Therapeutics PLC Financial Ratios

  • The Research & Development expenses have been 7,684.39% of Revenue.
  • The Interest Expense is -21.63% of Operating Income.
  • The Net Earning history of AUTL is -12,272.26% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 5 years.

Autolus Therapeutics PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AUTL
CUSIP: 05280R
Website: autolus.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AUTL Technical Analysis vs Fundamental Analysis

Sell
50
Autolus Therapeutics PLC (AUTL) is a Sell

Is Autolus Therapeutics PLC a Buy or a Sell?